IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
0.1713
-0.0248 (-12.65%)
Mar 31, 2025, 2:23 PM EDT - Market open

Company Description

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of solid and liquid tumors.

Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM and other cancers; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.

The company develops INB-300 and INB-500 that are in preclinical phase for treatment of acute myeloid leukemia, and other solid and hematological tumor types.

The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020.

IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.

IN8bio, Inc.
IN8bio logo
Country United States
Founded 2016
IPO Date Jul 30, 2021
Industry Biotechnology
Sector Healthcare
Employees 18
CEO Tai-Wei Ho

Contact Details

Address:
350 5th Avenue, Suite 5330
New York, New York 10118
United States
Phone 646 600 6438
Website in8bio.com

Stock Details

Ticker Symbol INAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $10.00
CIK Code 0001740279
CUSIP Number 45674E109
ISIN Number US45674E1091
Employer ID 82-5462585
SIC Code 2836

Key Executives

Name Position
Tai-Wei Ho Co-Founder, President, Chief Executive Officer and Director
Patrick McCall CPA Chief Financial Officer and Secretary
Dr. Kate Rochlin Ph.D. Chief Operating Officer
Dr. Lawrence S. Lamb Ph.D. Executive Vice President, Co-Founder and Chief Scientific Officer
Melissa Beelen Vice President of Clinical Operations

Latest SEC Filings

Date Type Title
Mar 17, 2025 ARS Filing
Mar 17, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 17, 2025 DEF 14A Other definitive proxy statements
Mar 13, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 13, 2025 10-K Annual Report
Mar 13, 2025 8-K Current Report
Mar 5, 2025 PRE 14A Other preliminary proxy statements
Mar 5, 2025 8-K Current Report
Mar 3, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing